Clinical Trials

 Inclusion Criteria:

• Men and women between the ages of 18-100.
• Non-arthritic or mildly arthritic knee joints.

Exclusion Criteria:

• Congenital malformation of the target knee resulting in significant deformity.
• Surgery on the index knee within 1 year of study enrollment.
• Injections of any into the index knee within 3 months prior to study enrollment.
• History of superficial infection in the index knee within 6 months of study enrollment, or evidence of current superficial infection affecting the index knee.
• Body mass index (BMI) > 40 kg/m^2.
• Taking anticoagulant medications (e.g., warfarin, heparin) or clopidogrel (Plavix).
• Taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within 3 months prior to study enrollment.
• On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including use of systemic steroids/corticosteroids.
• Systemic inflammatory, rheumatological or connective tissue disorder including but not   limited to rheumatoid arthritis, systemic sclerosis, system lupus erythematosus, and Ehlers-Danlos Syndrome.
• Rheumatological or inflammatory disease of the knee or chondrocalcinosis/calcium pyrophosphate disease (CPPD), hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget’s disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot’s knee joint, villonodular synovitis, and synovial chondromatosis.
• Ongoing infectious disease, including but not limited to tuberculosis, HIV, hepatitis, and syphilis.
• History of cancer/malignancy with the exception of adequately treated basal cell or squamous cell carcinoma of the skin not associated with the target knee within the last 5 years.
• History of blood dyscrasia, including but not limited to anemia, thrombocytopenia, and monoclonal gammopathy.
• Known allergy to local anesthetics of other components of the study drug.
• History of or current evidence of alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have use of medical marijuana within 30 days of study entry.
• Any illness or condition which, in the investigators’ judgement will interfere with the interpretation of the study results.

Eligibility last updated 10/1/21. Questions regarding updates should be directed to the study team contact.